Dr. Meisner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Mgh, 15 Parkman St
Boston, MA 02114Phone+1 617-319-1260
Summary
- Dr. Robert Meisner is a psychiatrist based in Boston, MA, specializing in child and adolescent psychiatry. He graduated from Harvard Medical School in 2008 and holds an AB from Princeton. His research focuses on treatment-resistant depression, with recent publications including work on electroconvulsive therapy, ketamine treatments, and a position statement on insurance coverage for ketamine. His studies have been cited multiple times, contributing to the fields of depression treatment and neurocognitive effects of psychiatric interventions.
Education & Training
Harvard Medical SchoolClass of 2008
Princeton AB, 1996 - 2000
Certifications & Licensure
MA State Medical License 2013 - 2025
DC State Medical License 2010 - 2014
VA State Medical License 2010 - 2013
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- Prediction of individual treatment allocation between electroconvulsive therapy or ketamine using the Personalized Advantage Index.Benjamin S C Wade, Ryan Pindale, James Luccarelli, Shuang Li, Robert C Meisner
NPJ Digital Medicine. 2025-02-27 - 3 citationsNational Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.Mark J Niciu, Robert C Meisner, Brent R Carr, Ali A Farooqui, David Feifel
Journal of Affective Disorders. 2024-02-01 - Individual Prediction of Optimal Treatment Allocation Between Electroconvulsive Therapy or Ketamine using the Personalized Advantage Index.Benjamin Wade, Ryan Pindale, Joan Camprodon, James Luccarelli, Shuang Li
Research Square. 2023-11-30
Press Mentions
- Could Group Therapy Get a Boost from Psychedelics?March 10th, 2021
‘A Train Wreck in Slow Motion’: San Diego VA Takes Suicidal Vets off TreatmentJune 6th, 2020
Clinicians Embracing New Depression Drug Esketamine with ‘Enthusiastic Caution’March 6th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
